Simcere Seeks Oncology Acquisitions, Ex-China Licensing Partners For Endu
This article was originally published in PharmAsia News
Executive Summary
Simcere Pharmaceutical Group plans to be one of the last China-based pharmaceutical firms standing after a predicted major consolidation could shrink that industry to as few as 1,000 companies in the next several years
You may also be interested in...
China SFDA Seeks Public Comment On Change To Proposed Definition Of “New” Drugs
Agency’s draft drug registration rules propose to eliminate China’s fast track approval process for certain types of drugs, including AIDS and oncologics.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).